Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Gastro-oesophageal reflux disease Age: Adult |
Dose: Intravenous Injection or Infusion – 20 mg or 40 mg Frequency: once daily Duration: less than 10 days Note: Administer injection over at least 3 minutes or infusion over 10-30 minutes. Convert to oral therapy as soon as possible. |
|
Indication: NSAID-associated ulceration Age: Adult |
Dose: Intravenous Injection or Infusion – 20 mg/day Note: Administer injection over at least 3 minutes or infusion over 10-30 minutes. Convert to oral therapy as soon as possible. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Short-term treatment of gastroesophageal reflux disease with erosive esophagitis Age: less than 1 month Condition: when oral therapy is not possible or appropriate |
Dose: Intravenous – Safety and efficacy not established Note: Safety and efficacy not established |
|
Indication: Short-term treatment of gastroesophageal reflux disease with erosive esophagitis Age: 1 month to 1 year Condition: when oral therapy is not possible or appropriate |
Dose: Intravenous – 0.5 mg/kg Frequency: once daily |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Not Specified Note: No dosage adjustment needed. |
Administration
- For IV use only
- Inject over 3 minutes
Side Effect
- Headache (2-11%)
- Flatulence (10%)
- Indigestion (6%)
- Nausea (6%)
- Abdominal pain (1-6%)
- Diarrhea (2-4%)
- Xerostomia (3-4%)
- Dizziness (2-3%)
- Constipation (2-3%)
- Somnolence (1-2%)
- Pruritus (1%)
- Blood and lymphatic system disorders Agranulocytosis
- pancytopenia
- Blurred vision
- GI disorders Pancreatitis
- stomatitis
- microscopic colitis
- Hepatobiliary disorders Hepatic failure
- hepatitis with or without jaundice
- Anaphylactic reaction/shock
- GI candidiasis
- Hypomagnesemia
- Muscular weakness
- myalgia
- bone fracture
- Hepatic encephalopathy
- taste disturbance
- Aggression
- agitation
- depression
- hallucination
- Interstitial nephritis
- Gynecomastia
- Bronchospasm
- Alopecia
- erythema multiforme
- hyperhidrosis
- photosensitivity
- Stevens-Johnson syndrome
- toxic epidermal necrolysis (sometimes fatal fatal)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Rilpivirine, atazanavir, nelfinavir
|
Potentially Fatal: May decrease serum concentration and pharmacological effects
|
|
Digoxin
|
Increased risk of digoxin-induced cardiotoxic effects
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Benzimidazole Hypersensitivity
|
Risk of allergic reaction
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.